-

11:27:56 PM

OCGN Stock News

OCGN - Ocugen Inc

05/24/23 8:36 AM

Nasdaq : OCGN

offering

Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock

Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the pricing of its underwritten public offering of 30,000,000 shares

RHEA-AI

neutral

05/23/23 4:01 PM

Nasdaq : OCGN

offering

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it has commenced an underwritten public offering of its common

RHEA-AI

neutral

05/23/23 8:00 AM

Nasdaq : OCGN

conferences

Ocugen to Present at BIO International Convention 2023

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present at the 2023 BIO

RHEA-AI

neutral

05/05/23 7:00 AM

Nasdaq : OCGN

earnings

Ocugen Provides Business Update with First Quarter 2023 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Announced Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400 for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Received Orphan Drug Designation (ODD) from the FDA for OCU410ST for

RHEA-AI

neutral

04/28/23 7:00 AM

Nasdaq : OCGN

conferencesearnings

Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and

RHEA-AI

neutral

04/27/23 7:25 AM

Nasdaq : OCGN

Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company

RHEA-AI

very positive

04/26/23 6:30 AM

Nasdaq : OCGN

conferences

Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman,

RHEA-AI

neutral

04/20/23 8:00 AM

Nasdaq : OCGN

conferences

Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company will present on its

RHEA-AI

neutral

04/14/23 7:45 AM

Nasdaq : OCGN

clinical trial

Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis

Favorable safety and tolerability profile related to OCU400 investigational product candidate Initial clinical data from low and medium dose cohorts indicates positive trend in Multi-luminance mobility testing and Best-Corrected Visual Acuity scores for OCU400 treated eyes 71.4% (5/7) of OCU400

RHEA-AI

positive

04/11/23 6:20 PM

Nasdaq : OCGN

conferences

Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

OCGN Data

IndustrySanitary Paper Product Manufacturing
Websiteocugen.com
CeoShankar Musunuri
Security nameOcugen Inc
Issue typecs
SectorManufacturing
Sic code3842
Employees56
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Sanitary Paper Product Manufacturing
Address5 Great Valley Pkwy Ste 160
StatePennsylvania
CityMalvern
Zip19355
CountryUS
Phone14843284698

About Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.